Erythropoietin improves glucose metabolism and pancreatic β-cell damage in experimental diabetic rats

Chen,Li‑Na; Sun,Qiang; Liu,Shu‑Qing; Hu,Hao; Lv,Juan; Ji,Wen‑Jun; Wang,Meng; Chen,Ming‑Xia; Zhou,Jun

doi:10.3892/mmr.2015.4006

Erythropoietin improves glucose metabolism and pancreatic β-cell damage in experimental diabetic rats

Authors:
- Li‑Na Chen
- Qiang Sun
- Shu‑Qing Liu
- Hao Hu
- Juan Lv
- Wen‑Jun Ji
- Meng Wang
- Ming‑Xia Chen
- Jun Zhou
View Affiliations

Affiliations: Department of Pharmacology, School of Basic Medical Sciences, Xian Jiaotong University Health Science Center, Xian, Shaanxi 710061, P.R. China, Department of Electron Microscopy Room, School of Basic Medical Sciences, Xian Jiaotong University Health Science Center, Xian, Shaanxi 710061, P.R. China
Published online on: June 29, 2015 https://doi.org/10.3892/mmr.2015.4006
Pages: 5391-5398

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have implicated erythropoietin (EPO) signaling in the regulation of glucose metabolism. Whether EPO can be used treat diabetes and the underlying mechanism remain to be elucidated. The present study aimed to investigate whether EPO affects glucose metabolism, and the underlying mechanisms, in experimental diabetic rats. The effects of EPO (300 U/kg three times a week for 4 weeks) on glucose metabolism, hematopoietic function, blood selenium content and the ultrastructure of pancreatic β‑cells were investigated in low dose (25 mg/kg body weight) streptozotocin‑induced experimental diabetic rats provided with a high‑fat diet. The results demonstrated that EPO significantly decreased the fasting blood glucose, the area under the curve of the oral glucose tolerance and insulin tolerance tests and L‑alanine gluconeogenesis. Ultrastructural examination of the pancreatic islets revealed that EPO prevented the dysfunction of pancreatic β‑cells in experimental diabetic rats, ameliorated cytoplasmic vacuolation and fragmentation of mitochondria, and increased the number of secretory granules. EPO administration increased the activities of superoxide dismutase and glutathione peroxidase, and decreased the level of malondialdehyde. Additionally, EPO increased blood selenium in the diabetic rats and produced a hematopoietic effect. These results indicated that EPO modulated glucose metabolism and improved pancreatic β‑cells damage by increasing anti‑oxidation. The detailed mechanisms underlying these effects require further investigation.

View Figures

View References

1	Chateauvieux S, Grigorakaki C, Morceau F, Dicato M and Diederich M: Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol. 82:1291–1303. 2011. View Article : Google Scholar : PubMed/NCBI
2	Zhang Y, Wang L, Dey S, Alnaeeli M, Suresh S, Rogers H, Teng R and Noguchi CT: Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci. 15:10296–10333. 2014. View Article : Google Scholar : PubMed/NCBI Choi D, Retnakaran R and Woo M: The extra-hematopoietic role of erythropoietin in diabetes mellitus. Curr Diabetes Rev. 7:284–290. 2011. View Article : Google Scholar : PubMed/NCBI
3	Choi D, Retnakaran R and Woo M: The extra-hematopoietic role of erythropoietin in diabetes mellitus. Curr Diabetes Rev. 7:284–290. 2011. View Article : Google Scholar : PubMed/NCBI
4	Chikuma M, Masuda S, Kobayashi T, Nagao M and Sasaki R: Tissue-specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am J Physiol Endocrinol Metab. 279:E1242–E1248. 2000.PubMed/NCBI
5	Lamon S, Zacharewicz E, Stephens AN and Russell AP: EPO-receptor is present in mouse C2C12 and human primary skeletal muscle cells but EPO does not influence myogenesis. Physiol Rep. 2:e002562014. View Article : Google Scholar : PubMed/NCBI
6	Dimitrijevic ZM, Cvetkovic TP, Djordjevic VM, Pavlovic DD, Stefanovic NZ, Stojanovic IR, Paunovic GJ and Velickovic-Radovanovic RM: How the duration period of erythropoietin treatment influences the oxidative status of hemodialysis patients. Int J Med Sci. 9:808–815. 2012. View Article : Google Scholar : PubMed/NCBI
7	Nairz M, Sonnweber T, Schroll A, Theurl I and Weiss G: The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect. 14:238–246. 2012. View Article : Google Scholar :
8	Chen S, Li J, Peng H, Zhou J and Fang H: Administration of erythropoietin exerts protective effects against glucocorticoid-induced osteonecrosis of the femoral head in rats. Int J Mol Med. 33:840–848. 2014.PubMed/NCBI
9	Stoyanoff TR, Todaro JS, Aguirre MV, Zimmermann MC and Brandan NC: Amelioration of lipopolysaccharide-induced acute kidney injury by erythropoietin: Involvement of mitochondria-regulated apoptosis. Toxicology. 318:13–21. 2014. View Article : Google Scholar : PubMed/NCBI
10	Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, et al China National Diabetes and Metabolic Disorders Study Group: Prevalence of diabetes among men and women in China. N Engl J Med. 362:1090–1101. 2010. View Article : Google Scholar : PubMed/NCBI
11	Janghorbani M and Amini M: Incidence of metabolic syndrome and its risk factors among type 2 diabetes clinic attenders in Isfahan, Iran. Endokrynol Pol. 63:372–380. 2012.PubMed/NCBI
12	Ohshima K, Mogi M, Jing F, Iwanami J, Tsukuda K, Min LJ, Ogimoto A, Dahlöf B, Steckelings UM, Unger T, et al: Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation. PLoS One. 7:e483872012. View Article : Google Scholar
13	Fenjves ES, Ochoa MS, Cabrera O, Mendez AJ, Kenyon NS, Inverardi L and Ricordi C: Human, nonhuman primate, and rat pancreatic islets express erythropoietin receptors. Transplantation. 75:1356–1360. 2003. View Article : Google Scholar : PubMed/NCBI
14	Kwon MS, Kim MH, Kim SH, Park KD, Yoo SH, Oh IU, Pak S and Seo YJ: Erythropoietin exerts cell protective effect by activating PI3K/Akt and MAPK pathways in C6 Cells. Neurol Res. 36:215–223. 2014. View Article : Google Scholar : PubMed/NCBI
15	Fenjves ES, Ochoa MS, Gay-Rabinstein C, Molano RD, Pileggi A, Mendez AJ, Inverardi L and Ricordi C: Adenoviral gene transfer of erythropoietin confers cytoprotection to isolated pancreatic islets. Transplantation. 77:13–18. 2004. View Article : Google Scholar : PubMed/NCBI
16	Wietecha-Posłuszny R, Lech T and Kościelniak P: Application of three spectrometric methods to total selenium determination in postmortem material in a case of acute selenium compound poisoning. J Forensic Sci. 56:518–521. 2011. View Article : Google Scholar
17	Wang Q, Pfister F, Dorn-Beineke A, vom Hagen F, Lin J, Feng Y and Hammes HP: Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina. Diabetologia. 53:1227–1238. 2010. View Article : Google Scholar : PubMed/NCBI
18	Benstoem C, Goetzenich A, Kraemer S, Borosch S, Manzanares W, Hardy G and Stoppe C: Selenium and its supplementation in cardiovascular disease-what do we know? Nutrients. 7:3094–3118. 2015. View Article : Google Scholar : PubMed/NCBI
19	Christensen B, Nellemann B, Larsen MS, Thams L, Sieljacks P, Vestergaard PF, Bibby BM, Vissing K, Stødkilde-Jørgensen H, Pedersen SB, et al: Whole body metabolic effects of prolonged endurance training in combination with erythropoietin treatment in humans: A randomized placebo controlled trial. Am J Physiol Endocrinol Metab. 305:E879–E889. 2013. View Article : Google Scholar : PubMed/NCBI
20	Kristensen PL, Høi-Hansen T, Olsen NV, Pedersen-Bjergaard U and Thorsteinsson B: Erythropoietin during hypoglycaemia in type 1 diabetes: Relation to basal renin-angiotensin system activity and cognitive function. Diabetes Res Clin Pract. 85:75–84. 2009. View Article : Google Scholar : PubMed/NCBI
21	Wang L, Teng R, Di L, Rogers H, Wu H, Kopp JB and Noguchi CT: PPARα and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders. Diabetes. 62:4122–4131. 2013. View Article : Google Scholar : PubMed/NCBI
22	Pan Y, Shu JL, Gu HF, Zhou DC, Liu XL, Qiao QY, Fu SK, Gao FH and Jin HM: Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes. Mol Cell Endocrinol. 367:116–123. 2013. View Article : Google Scholar : PubMed/NCBI
23	Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU and Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 355:2071–2084. 2006. View Article : Google Scholar : PubMed/NCBI
24	Rosengren AH, Braun M, Mahdi T, Andersson SA, Travers ME, Shigeto M, Zhang E, Almgren P, Ladenvall C, Axelsson AS, et al: Reduced insulin exocytosis in human pancreatic β-cells with gene variants linked to type 2 diabetes. Diabetes. 61:1726–1733. 2012. View Article : Google Scholar : PubMed/NCBI
25	Tersey SA, Nishiki Y, Templin AT, Cabrera SM, Stull ND, Colvin SC, Evans-Molina C, Rickus JL, Maier B and Mirmira RG: Islet β-cell endoplasmic reticulum stress precedes the onset of 1 diabetes in the nonobese diabetic mouse model. Diabetes. 61:818–827. 2012. View Article : Google Scholar : PubMed/NCBI
26	He H, Wu T, Xiong J, Chen K and Mo Z: Effect of erythropoietin on the proliferation and apoptosis of neonatal porcine islet cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 35:1115–1122. 2010.PubMed/NCBI
27	Shuai H, Zhang J, Zhang J, Xie J, Zhang M, Yu Y and Zhang L: Erythropoietin protects pancreatic β-cell line NIT-1 cells against cytokine-induced apoptosis via phosphatidylinositol 3-kinase/Akt signaling. Endocr Res. 36:25–34. 2011. View Article : Google Scholar
28	Yan LJ: Pathogenesis of chronic hyperglycemia: From reductive stress to oxidative stress. J Diabetes Res. 2014:1379192014. View Article : Google Scholar : PubMed/NCBI
29	Yu T, Li L, Bi Y, Liu Z, Liu H and Li Z: Erythropoietin attenuates oxidative stress and apoptosis in Schwann cells isolated from streptozotocin-induced diabetic rats. J Pharm Pharmacol. 66:1150–1160. 2014.PubMed/NCBI
30	Luo YH, Li ZD, Liu LX and Dong GH: Pretreatment with erythropoietin reduces hepatic ischemia-reperfusion injury. Hepatobiliary Pancreat Dis Int. 8:294–299. 2009.PubMed/NCBI
31	Yang FL, Subeq YM, Chiu YH, Lee R P, Lee CJ and Hsu BG: Recombinant human erythropoietin reduces rhabdomyolysis-induced acute renal failure in rats. Injury. 43:367–373. 2012. View Article : Google Scholar : PubMed/NCBI
32	Liu N, Tian J, Wang W, Cheng J, Hu D and Zhang J: Effect and mechanism of erythropoietin on mesenchymal stem cell proliferation in vitro under the acute kidney injury microenvironment. Exp Biol Med (Maywood). 236:1093–1099. 2011. View Article : Google Scholar
33	Stapleton SR: Selenium: An insulin-mimetic. Cell Mol Life Sci. 57:1874–1879. 2000. View Article : Google Scholar
34	Rocourt CR and Cheng WH: Selenium supranutrition: Are the potential benefits of chemoprevention outweighed by the promotion of diabetes and insulin resistance? Nutrients. 5:1349–1365. 2013. View Article : Google Scholar : PubMed/NCBI
35	Wang C, Yang S, Zhang N, Mu Y, Ren H, Wang Y and Li K: Long-term supranutritional supplementation with selenate decreases hyperglycemia and promotes fatty liver degeneration by inducing hyperinsulinemia in diabetic db/db mice. PLoS One. 9:e1013152014. View Article : Google Scholar : PubMed/NCBI
36	Labunskyy VM, Lee BC, Handy DE, Loscalzo J, Hatfield DL and Gladyshev VN: Both maximal expression of selenoproteins and selenoprotein deficiency can promote development of type 2 diabetes-like phenotype in mice. Antioxid Redox Signal. 14:2327–2336. 2011. View Article : Google Scholar : PubMed/NCBI
37	Stranges S, Sieri S, Vinceti M, Grioni S, Guallar E, Laclaustra M, Muti P, Berrino F and Krogh V: A prospective study of dietary selenium intake and risk of type 2 diabetes. BMC Public Health. 10:5642010. View Article : Google Scholar : PubMed/NCBI
38	Thomas MC: The high prevalence of anemia in diabetes is linked to functional erythropoietin deficiency. Semin Nephrol. 26:275–282. 2006. View Article : Google Scholar : PubMed/NCBI
39	Choi D, Schroer SA, Lu SY, Wang L, Wu X, Liu Y, Zhang Y, Gaisano H Y, Wagner KU, Wu H, et al: Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med. 207:2831–2842. 2010. View Article : Google Scholar : PubMed/NCBI
40	Wang Q, Gorbey S, Pfister F, Höger S, Dorn-Beineke A, Krügel K, Berrone E, Wu L, Korff T, Lin J, et al: Long-term treatment with suberythropoietic Epo is vaso- and neuroprotective in experimental diabetic retinopathy. Cell Physiol Biochem. 27:769–782. 2011. View Article : Google Scholar : PubMed/NCBI